跳至主要内容
临床试验/NCT03358511
NCT03358511已完成不适用

Engineering Gut Microbiome to Target Breast Cancer

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2017年10月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
7
试验地点
2
主要终点
Mean number of cytotoxic T lymphocytes (CD8+ cells)

研究概览

简要总结

The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel might help improve immune system, particularly the ability of immune system to recognize cancer. This study will investigate how probiotics will affect the subjects' immune system on breast cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Post-menopausal females ≥ 18 years of age
  • Histologically confirmed adenocarcinoma of the breast ≥1.0 cm operable stage I-III
  • Must have adequate organ function,
  • Not receive systemic neoadjuvant therapy
  • Be willing to provide tissue, blood, and stool samples for research study.
  • Must not have taken any probiotics in the past 60 days prior to enrollment.

排除标准

  • Patients with autoimmune disease, immune deficiency such as HIV, irritable bowel, known diverticulosis, and other serious GI conditions at treating physician's discretion will be excluded.

结局指标

主要结局

Mean number of cytotoxic T lymphocytes (CD8+ cells)

时间窗: Approximately 4 weeks after baseline

CD8+ T cells (often called cytotoxic T lymphocytes) are very important for immune defence against intracellular pathogens, including viruses and bacteria, and for tumor surveillance.

次要结局

未报告次要终点

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Saranya Chumsri

Associate Professor of Medicine

Mayo Clinic

研究点 (2)

Loading locations...

相似试验

Engineering Gut Microbiome to Target Breast Cancer | 临床试验